ProMIS Neurosci (PMN) Gets a Buy Rating from Noble Financial

By Carrie Williams

In a new note to investors on February 14, an analyst has provided a rating update for ProMIS Neurosci (PMNResearch Report). The company received a Buy on February 14 from Noble Financial’s analyst Cosme Ordonez, with a C$1 price target.

Read also: Bausch Health Companies (BHC): Bausch + Lomb Granted FDA 510(K) Clearance for Coating Technology

The word on The Street in general, suggests a Hold analyst consensus rating for ProMIS Neurosci.

Based on ProMIS Neurosci’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of C$2.91 million. In comparison, last year the company had a GAAP net loss of C$1.13 million.

ProMIS Neurosciences, Inc. operates as a development stage biotech company. It discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular Alzheimer’s disease and amyotrophic lateral sclerosis.

The company’s shares closed on Friday at C$0.27.